[EN] COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS [FR] THERAPIE DE COMBINAISON AVEC DES INHIBITEURS DE LA SYNTHASE DU MONOXYDE D'AZOTE INDUCTIBLE ET DES AGENTS D'ALKYLATION
Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor
申请人:——
公开号:US20040077639A1
公开(公告)日:2004-04-22
Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.
Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
申请人:——
公开号:US20040087653A1
公开(公告)日:2004-05-06
Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.
Methods for treatment and prevention of gastrointestinal conditions
申请人:——
公开号:US20040127569A1
公开(公告)日:2004-07-01
Therapeutic methods for the prevention and treatment of conditions and diseases of the gastrointestinal tract involving an overproduction of nitric oxide by inducible nitric oxide synthase are described, the methods including administering to a subject in need thereof a therapeutically effective amount of a selective inhibitor of inducible nitric oxide synthase (iNOS). The methods also include the use of selective inhibitors of iNOS in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents.
2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
申请人:Durley C. Richard
公开号:US20050256199A1
公开(公告)日:2005-11-17
The present invention relates to 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.